Compare Gold Fields Limited (GFI) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Heron Therapeutics Inc — how do they compare? Gold Fields Limited trades at $41.13 (market cap $36.07B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Gold Fields Limited is far larger — about 586.8× Heron Therapeutics Inc's market cap, and Gold Fields Limited pays a 5.76% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GFI | HRTX | |
|---|---|---|
Market Cap | $36.07B | $61.47M |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $1.49 |
52-Week Low | $29.31 | $0.32 |
Enterprise Value | $37.51B | $168.21M |
Dividend Yield | 5.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields Limited (GFI) trades at $41.12, up 0.73% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 40.76% net income margin and ROE of 52.33%, though recent quarterly earnings missed expectations. Revenue grew to $5.2B in 2024, with net income reaching $1.25B. Analyst consensus is a Buy with a $52 price target, indicating 26% upside potential.
The outlook for GFI is positive given its robust fundamentals and gold price tailwinds, but risks include volatile earnings performance and rising debt levels. Institutional accumulation and favorable sector sentiment support the bullish case, though investors should monitor cost pressures and execution on growth targets.
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
